Search academic texts

Information × Registration Number 0221U104831, 0120U002185 , R & D reports Title To determine the optimal methods of high-energy brachytherapy with a source of ionizing radiation iridium-192 in the treatment of patients with secondary cancer of the vagina, taking into account the molecular and biological features of the tumor. popup.stage_title Head Ivankova Valentina S., Доктор медичних наук Registration Date 25-04-2021 Organization National Cancer Institute popup.description2 The subject of the study was 33 patients with secondary vaginal cancer. The quality control program of the linear electron accelerator "Clinac 2100 CD" for conformal radiation therapy (CPT) of patients with secondary vaginal cancer has been developed; defined stages and sequence of topometric preparation and planning of conformal irradiation and contact PT sources of 192Ir high activity (HDR) for patients with secondary vaginal cancer; developed methods of chemo-radiation therapy (CPT) for patients with secondary vaginal cancer using cytostatic drugs (fluorofur, cisplatin) as radiomodifiers during conformal PT, as well as HDR 192Ir-brachytherapy according to different regimes and MDR 60Co-brachytherapy according to standards. The study included 33 patients with secondary vaginal cancer who underwent CPT at the first stage of combined radiation therapy (CPT): a single focal dose (ROD) of 2.0 Gy was applied to the pelvic area to a total focal dose (SOD) of 30-40 Gy. , taking into account the radiation dose summed up during the previous radiation treatment. At the second stage of the course of PPT, patients of all groups underwent high-energy (HDR) intracavitary brachytherapy (BT) with 192Ir (GammaMed plus IX) or 60Co (GyneSource) sources. Depending on the source and mode of irradiation, patients are divided into two main and control groups. I main group consisted of 11 patients with secondary vaginal cancer, to whom HDR BT was performed with 192Ir sources according to the regime: GENDER = 3 Gy x 2 g / week. The II main group included 10 patients with secondary vaginal cancer, to whom HDR BT was performed with 192Ir sources according to the regime: GENUS = 6 Gy x 1 g / week. The control group consisted of 12 patients with secondary vaginal cancer, to whom BT was performed with sources of 60Co mean activity (MDR) according to the regime: GENUS = 6 Gy x 1 g / week. Product Description popup.authors Buckeye Olga O. Baranovska Lidiia M. Galyas Oksana V. Paliy Maxim І. Khrulenko Tatiana V. popup.nrat_date 2021-04-25 Close